コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab o
6 atic function occurred in 5 patients in each fremanezumab group (1%) and 3 patients in the placebo gr
8 The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons
9 g at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at w
10 with fremanezumab quarterly, 4.6+/-0.3 with fremanezumab monthly, and 2.5+/-0.3 with placebo (P<0.00
12 the fremanezumab-quarterly group, 41% in the fremanezumab-monthly group, and 18% in the placebo group
13 action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked
15 In addition, when given sufficient time, fremanezumab prevents the activation and sensitization o
16 days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single dose of 675 mg at basel
17 ents enrolled, 376 were randomly assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and
18 f headache days per month was 4.3+/-0.3 with fremanezumab quarterly, 4.6+/-0.3 with fremanezumab mont
19 er of headache days per month was 38% in the fremanezumab-quarterly group, 41% in the fremanezumab-mo
21 ral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, a
22 dy was to better understand how the CGRP-mAb fremanezumab (TEV-48125) modulates meningeal sensory pat
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。